# Ole Kleist Jeppesen

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/ole-kleist-jeppesen/

## Facts

| Field | Value |
| --- | --- |
| Citations | 5,587 |
| Field | Diabetes Treatment and Management |
| h-index | 15 |
| i10-index | 16 |
| Last Known Institution | Novo Nordisk (Denmark) |
| OpenAlex ID | https://openalex.org/A5055974284 |
| Works | 53 |

## Researcher papers

- [Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes](https://scholariq.org/papers/oral-semaglutide-and-cardiovascular-outcomes-in-patients-with-type-2-diabetes/)
- [Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial](https://scholariq.org/papers/semaglutide-2-4-mg-once-a-week-in-adults-with-overweight-or-obesity-and-type-2/)
- [Once-Weekly Semaglutide in Adolescents with Obesity](https://scholariq.org/papers/once-weekly-semaglutide-in-adolescents-with-obesity/)
- [PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes](https://scholariq.org/papers/pioneer-1-randomized-clinical-trial-of-the-efficacy-and-safety-of-oral/)
- [Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial](https://scholariq.org/papers/long-term-weight-loss-effects-of-semaglutide-in-obesity-without-diabetes-in-the/)
- [Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk](https://scholariq.org/papers/semaglutide-sustain-and-pioneer-reduces-cardiovascular-events-in-type-2-diabetes/)
- [Exogenous Natural Surfactant for Treatment of Acute Lung Injury and the Acute Respiratory Distress Syndrome](https://scholariq.org/papers/exogenous-natural-surfactant-for-treatment-of-acute-lung-injury-and-the-acute/)
- [Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial](https://scholariq.org/papers/semaglutide-and-cardiovascular-outcomes-by-baseline-and-changes-in-adiposity/)
- [Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: Rationale, design and patient baseline characteristics for the PIONEER 6 trial](https://scholariq.org/papers/cardiovascular-safety-of-oral-semaglutide-in-patients-with-type-2-diabetes/)
- [Effect of Semaglutide on Regression and Progression of Glycemia in People With Overweight or Obesity but Without Diabetes in the SELECT Trial](https://scholariq.org/papers/effect-of-semaglutide-on-regression-and-progression-of-glycemia-in-people-with/)
- [Kidney and Survival Outcomes with Semaglutide by CKD Severity in the FLOW Trial](https://scholariq.org/papers/kidney-and-survival-outcomes-with-semaglutide-by-ckd-severity-in-the-flow-trial/)
- [Effect of semaglutide on COVID-19 and other infections: an analysis from the FLOW randomized clinical trial](https://scholariq.org/papers/effect-of-semaglutide-on-covid-19-and-other-infections-an-analysis-from-the-flow/)

## Researcher topics

- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)
- [Metabolism, Diabetes, and Cancer](https://scholariq.org/topics/metabolism-diabetes-and-cancer/)
- [Bariatric Surgery and Outcomes](https://scholariq.org/topics/bariatric-surgery-and-outcomes/)
- [Diabetes, Cardiovascular Risks, and Lipoproteins](https://scholariq.org/topics/diabetes-cardiovascular-risks-and-lipoproteins/)
- [Chronic Kidney Disease and Diabetes](https://scholariq.org/topics/chronic-kidney-disease-and-diabetes/)

## Researcher university

- [Novo Nordisk (Denmark)](https://scholariq.org/institutions/novo-nordisk-denmark/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.